Completed PHASE3 INTERVENTIONAL 3-arm NCT01285115

The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form

Phase 3 The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form : A Randomized, Double Blind, Parallel-controlled Trial

Sponsor: Korea Health Industry Development Institute

Conditions Generalized Anxiety Disorder

Interventions KyungBangn Gamisoyosan KyungBangn-Gamisoyosan-x-gwarip Placebo

Updated 5 times since 2017 Last updated: Jan 26, 2011 Started: Dec 31, 2008 Primary completion: Jun 30, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01285115, this PHASE3 trial focuses on Generalized Anxiety Disorder and remains completed. Sponsored by Korea Health Industry Development Institute, it has been updated 5 times since 2008, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korea Health Industry Development Institute

Data source: Korea Health Industry Development Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Daejeon, South Korea